Murex Diagnostics/Organon Teknika
This article was originally published in The Gray Sheet
Executive Summary
Permanently enjoined from manufacturing and selling hepatitis C virus immunoassays that infringe patents held by Chiron, according to a Nov. 29 ruling by the High Court of Justice for England and Wales on a suit brought by Chiron and its marketing partner, Johnson & Johnson's Ortho Diagnostic Systems. Murex said it will appeal the judge's decision to stay the injunction and "will sustain an annual negative revenue impact of $3 mil. on sales of hepatitis C products in the U.K. pending the outcome of the appeal." Damages will be determined at a future hearing
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.